首页> 美国卫生研究院文献>Blood Advances >g(HbF): a genetic model of fetal hemoglobin in sickle cell disease
【2h】

g(HbF): a genetic model of fetal hemoglobin in sickle cell disease

机译:g(HbF):镰状细胞病中胎儿血红蛋白的遗传模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Fetal hemoglobin (HbF) is a strong modifier of sickle cell disease (SCD) severity and is associated with 3 common genetic loci. Quantifying the genetic effects of the 3 loci would specifically address the benefits of HbF increases in patients. Here, we have applied statistical methods using the most representative variants: rs1427407 and rs6545816 in BCL11A, rs66650371 (3-bp deletion) and rs9376090 in HMIP-2A, rs9494142 and rs9494145 in HMIP-2B, and rs7482144 (Xmn1-HBG2 in the β-globin locus) to create g(HbF), a genetic quantitative variable for HbF in SCD. Only patients aged ≥5 years with complete genotype and HbF data were studied. Five hundred eighty-one patients with hemoglobin SS (HbSS) or HbSβ0 thalassemia formed the “discovery” cohort. Multiple linear regression modeling rationalized the 7 variants down to 4 markers (rs6545816, rs1427407, rs66650371, and rs7482144) each independently contributing HbF-boosting alleles, together accounting for 21.8% of HbF variability (r2) in the HbSS or HbSβ0 patients. The model was replicated with consistent r2 in 2 different cohorts: 27.5% in HbSC patients (N = 186) and 23% in 994 Tanzanian HbSS patients. g(HbF), our 4-variant model, provides a robust approach to account for the genetic component of HbF in SCD and is of potential utility in sickle genetic and clinical studies.
机译:胎儿血红蛋白(HbF)是镰状细胞疾病(SCD)严重程度的强力调节剂,并且与3个常见的遗传基因座相关。量化这3个基因座的遗传效应将特别解决HbF增加对患者的益处。在这里,我们应用了具有代表性的变体的统计方法:BCL11A中的rs1427407和rs6545816,HMIP-2A中的rs66650371(删除了3个碱基)和rs9376090,HMIP-2B中的rs9494142和rs9494145,以及rs7482144(β中的Xmn1-HBG2 -globin位点)以创建g(HbF),这是SCD中HbF的遗传定量变量。仅对年龄≥5岁且具有完整基因型和HbF数据的患者进行研究。 581名患有血红蛋白SS(HbSS)或HbSβ 0 地中海贫血的患者组成了“发现”队列。多元线性回归建模将7个变异合理化至4个标记(rs6545816,rs1427407, rs66650371 rs7482144 ),每个均独立地 贡献了增强HbF的等位基因。 ,占HbSS或HbSβ 0 患者HbF变异性( r 2 )的21.8%。在两个不同的队列中以一致的 r 2 复制该模型:HbSC患者(N = 186)为27.5%,坦桑尼亚994名HbSS患者为23%。我们的4变量模型 g(HbF)提供了一种可靠的方法来解释SCD中HbF的遗传成分,并且在镰刀基因和临床研究中具有潜在的实用性。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号